Products

Host Response

We are developing point-of-care, multiplex tests for host-response biomarkers in blood.

Discover more

Sepsis facts

Worldwide

Affects 30 million people, 6 million deaths annually.

Speed matters

Sepsis can progress rapidly and can be fatal. Each hour of delay in giving antibiotics increases risk of death by 7%.

High cost

Costs $27 billion annually in the U.S.

Host-Response Diagnostics

Host-response biomarkers are associated with inflammation and can be measured early in acute infection. Research indicates that certain combinations of these biomarkers may be prognostic for cytokine storm, which is an out-of-control immune response that is and associated with bad outcomes in COVID-19 and sepsis. Our panels will provide rapid results that may give insights about immune response, help inform treatment decisions and direct resource allocation in a crisis.

Clinical Utility of Host-Response Panels

Intended UseAction
Diagnosis
Differentiate between infectious vs. non-infectious etiology
Determine the need for broad spectrum antibiotics vs. COVID-19 intervention vs. non-infectious intervention
Staging
Where the patient is on the disease continuum: low-risk to cytokine storm?
Determine the need for broad spectrum antibiotics vs. COVID-19 intervention vs. non-infectious intervention
Monitoring
Assess response to treatment
Can antibiotics be de-escalated?
Should treatment be more aggressive?
Products are under development and not available for sale.

Partner with us

Contact us to learn more about our sepsis and host-response programs, or to partner with us in clinical studies.